Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Predicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models

Ahmet Celal Toprak, Mutlu Mete, Julia J. Shi, Daria V. Babushok, Carmelo Gurnari, Jaroslaw P. Maciejewski, Zoe Bass, Zehra Tombul, Carlos. I. A. Santos, Munevver N. Duran, Hussein Awada, Ibrahim Ibrahim, Alper Olcal, Yusuf Ozcan, Leslie Guerrero, Julio Alvarenga Thiebaud, Taha Bat

Blood Neoplasia (2025) 2 (4): 100163.

https://doi.org/10.1016/j.bneo.2025.100163

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients

Ghaith Abu-Zeinah, Anthony M. Hunter, Joseph J. Shatzel, Abdulraheem Yacoub, Albert Qin, Hung-Lun Chien, Ruben A. Mesa

Blood Neoplasia (2025) 2 (4): 100167.

https://doi.org/10.1016/j.bneo.2025.100167

Published: 2025

Includes: Supplemental data

Journal Articles

Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts

Stefania Leone, Francesco Grimaldi, Mara Memoli, Giulia Scalia, Annamaria Vincenzi, Maria Di Perna, Giuseppe Cerciello, Antonio Vassallo, Fabrizio Pane, Alessandra Picardi, Giuseppe Terrazzano, Giuseppina Ruggiero, Flavia Carriero, Valentina Rubino

Blood Neoplasia (2025) 2 (4): 100170.

https://doi.org/10.1016/j.bneo.2025.100170

Published: 2025

Includes: Supplemental data

Journal Articles

Application of the International Working Group MDS molecular taxonomy classes to a single institution cohort

Rohiverth Guarecuco, Lisa Yuen, Maxwell Roth, Brandon J. Aubrey, Andrew M. Brunner, Robert P. Hasserjian

Blood Neoplasia (2025) 2 (4): 100162.

https://doi.org/10.1016/j.bneo.2025.100162

Published: 2025

Includes: Supplemental data

Journal Articles

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

Rong Wang, Jessica M. Stempel, Rory M. Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Jan Philipp Bewersdorf, Lourdes Mendez, Xiaomei Ma, Nikolai A. Podoltsev

Blood Neoplasia (2025) 2 (4): 100159.

https://doi.org/10.1016/j.bneo.2025.100159

Published: 2025

Journal Articles

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

Abdulraheem Yacoub, Haris Ali, Vikas Gupta, Eunice S. Wang, Mrinal M. Patnaik, Gary J. Schiller, Minakshi Taparia, Tariq I. Mughal, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju

Blood Neoplasia (2025) 2 (4): 100165.

https://doi.org/10.1016/j.bneo.2025.100165

Published: 2025

Includes: Supplemental data

Journal Articles

MNT: a new target for AML

Karla C. Fischer, Veronique Litalien, Sarah T. Diepstraten, Michelle Jahja, Fiona C. Brown, Gemma L. Kelly, Andrew H. Wei, Suzanne Cory

Blood Neoplasia (2025) 2 (4): 100149.

https://doi.org/10.1016/j.bneo.2025.100149

Published: 2025

Includes: Supplemental data

Journal Articles

Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia

Blood Neoplasia (2025) 2 (4): 100166.

https://doi.org/10.1016/j.bneo.2025.100166

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of STAT3 in acute myeloid leukemia favors tissue infiltration linked to CXCR4 signaling

Bernhard Zdársky, Sophie Edtmayer, Agnieszka Witalisz-Siepracka, Stefanie Weiss, Stefanie Boigenzahn, Kerstin Heindl, Safia Zahma, Balázs Győrffy, Richard Moriggl, Dagmar Stoiber

Blood Neoplasia (2025) 2 (4): 100158.

https://doi.org/10.1016/j.bneo.2025.100158

Published: 2025

Includes: Supplemental data

Journal Articles

A comparative assessment of molecular-based prognostic models in CMML

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Akriti G. Jain, David A. Sallman, Andrew T. Kuykendall, Alison R. Walker, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji

Blood Neoplasia (2025) 2 (4): 100116.

https://doi.org/10.1016/j.bneo.2025.100116

Published: 2025

Includes: Supplemental data

Journal Articles

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1 -mutated acute myeloid leukemia: a real-world study

Curtis A. Lachowiez, B. Douglas Smith, Alexander Joseph Ambinder, Gary Binder, Anne Angiolillo, Ravi Potluri, Eros Papademetriou, Thomas W. LeBlanc

Blood Neoplasia (2025) 2 (4): 100152.

https://doi.org/10.1016/j.bneo.2025.100152

Published: 2025

Journal Articles

Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinib

Emily C. Liang, Cecelia Perkins, Rong Lu, Hongliang Shi, Saša Dimitrijević, Justin Abuel, Cheryl Langford, Parveen Abidi, Lenn Fechter, William Shomali, Jason Gotlib

Blood Neoplasia (2025) 2 (4): 100127.

https://doi.org/10.1016/j.bneo.2025.100127

Published: 2025

Includes: Supplemental data

Journal Articles

How to drug a leukemic stem cell: deciphering heterogeneity for better specificity

Alice Worker, Nicholas Jinks, Peter Woodmancy, Claire Seedhouse, Sophie G. Kellaway

Blood Neoplasia (2025) 2 (4): 100146.

https://doi.org/10.1016/j.bneo.2025.100146

Published: 2025

Journal Articles

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis

Fang Zhou, Biljana Culjkovic-Kraljacic, Christian Bach, Li Feng, Yuta Mishima, Katherine L. B. Borden, Daniel G. Tenen

Blood Neoplasia (2025) 2 (4): 100132.

https://doi.org/10.1016/j.bneo.2025.100132

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Ritul Sharma, Chunfen Zhang, Ravi Shah, Melanie M. Frigault, Amy J. Johnson, David Spencer Mangum, Luke D. Maese, Norman J. Lacayo, Aru Narendran

Blood Neoplasia (2025) 2 (4): 100148.

https://doi.org/10.1016/j.bneo.2025.100148

Published: 2025

Includes: Supplemental data

Journal Articles

Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3 mut AML

Toshiki Terao, Ken-ichi Matsuoka, Takumi Kondo, Yoshinobu Maeda

Blood Neoplasia (2025) 2 (4): 100141.

https://doi.org/10.1016/j.bneo.2025.100141

Published: 2025

Journal Articles

SRSF2 mutations in CCUS, MDS and AML: a cross-entity study

Sandra Huber, Sarah Ochmann, Stephan Hutter, Veronika Ecker, Manja Meggendorfer, Gregor Hoermann, Torsten Haferlach, Claudia Haferlach, Isolde Summerer

Blood Neoplasia (2025) 2 (4): 100144.

https://doi.org/10.1016/j.bneo.2025.100144

Published: 2025

Includes: Supplemental data

Journal Articles

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia (2025) 2 (4): 100145.

https://doi.org/10.1016/j.bneo.2025.100145

Published: 2025

Journal Articles

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern, Gabriel Ghiaur, Lukasz P Gondek, William Brian Dalton, Theodoros Karantanos, Tania Jain, Gabrielle T Prince, Richard J Jones, B. Douglas Smith, Alexander J Ambinder

Blood Neoplasia (2025) 2 (4): 100133.

https://doi.org/10.1016/j.bneo.2025.100133

Published: 2025

Includes: Supplemental data

Journal Articles

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba

Blood Neoplasia (2025) 2 (4): 100123.

https://doi.org/10.1016/j.bneo.2025.100123

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Predicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models

Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients

Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts

Application of the International Working Group MDS molecular taxonomy classes to a single institution cohort

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

MNT: a new target for AML

Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia

Loss of STAT3 in acute myeloid leukemia favors tissue infiltration linked to CXCR4 signaling

A comparative assessment of molecular-based prognostic models in CMML

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1 -mutated acute myeloid leukemia: a real-world study

Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinib

How to drug a leukemic stem cell: deciphering heterogeneity for better specificity

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3 mut AML

SRSF2 mutations in CCUS, MDS and AML: a cross-entity study

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only